Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
University of California, San Francisco
Ohio State University Comprehensive Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Mayo Clinic
University of Iowa
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Mayo Clinic
City of Hope Medical Center
Mayo Clinic
University of Washington
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Vanderbilt-Ingram Cancer Center
Mayo Clinic